Abstract: The present disclosure describes how a master beacon having a known UUID can be used to capture beacons within its range and superimpose a systematic address scheme on those beacons. The superimposed address scheme can then be used as a proxy for the individual beacons when developing applications that make use of the beacons. A master beacon automatically detects each beacon in a plurality of beacons and, for a set of beacons in the plurality of beacons, automatically changes either the first profile identifier or the second profile identifier for each beacon in the set of beacons. The change is such that the first profile identifier or the second profile identifier is identical for each beacon in the set of beacons and is also associated with the master beacon.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Also disclosed are pharmaceutical compositions that include PNPLA3 RNAi agents and methods of use thereof. The PNPLA3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the PNPLA3 RNAi agents in vivo provides for inhibition of PNPLA3 gene expression. The RNAi agents can be used in methods of treatment of PNPLA3-related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.

Abstract: Embodiments of this application provide a method for selecting a network, applied to an electronic device, the method including: receiving a redirect message, where the redirect message carries information about a first frequency: selecting, based on a signal parameter of the first frequency and a signal parameter of a prior frequency, a target frequency from the first frequency and the prior frequency; and redirecting to a cell at the target frequency. It can be seen that after receiving the redirect message, the electronic device selects, based on the signal parameter of the frequency carried in the redirect message and the signal parameter of the prior frequency, the target frequency to be redirected to. Compared with a manner of redirecting to a cell at the frequency carried in the redirect message, the method is more conducive to selecting a frequency at which a signal is better, and further redirecting to a network in which a signal is better.

Abstract: Embodiments of present invention provide a linear-drive pluggable optics (LPO) transceiver. The LPO transceiver includes a receiver path, which includes a receiver optical subassembly (ROSA) converting an input optical signal into an ingress electrical signal; and a linear transimpedance amplifier (TIA) with adjustable frequency transfer function (AFTF), the ingress electrical signal passing through the linear TIA to a host. The LPO transceiver also includes a transmitter path, which includes a linear driver with AFTF receiving an egress electrical signal from the host; and a transmitter optical subassembly (TOSA) converting the egress electrical signal from the linear driver to an output optical signal. A method of operating the LPO transceiver is also included.

Abstract: Described are RNAi agents, e.g., double stranded RNAi agents, for inhibiting patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Also disclosed are pharmaceutical compositions that include PNPLA3 RNAi agents and methods of use thereof. The PNPLA3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the PNPLA3 RNAi agents in vivo provides for inhibition of PNPLA3 gene expression. The RNAi agents can be used in methods of treatment of PNPLA3-related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.

Abstract: The present application discloses a communication method, a server, and a computer device. The communication method includes that a server establishes a connection and feeds back a display control in response to requests of a first terminal and a second terminal; then, the server feeds back function feedback information in response to a function request of the first terminal, and feeds back function feedback information in response to a menu request of the second terminal; and the servers presents multiple interface components and maintains and updates each interface component in response to management operation of a third user.

Abstract: The present application discloses a communication method, a terminal, a server, a communication system, a computer device and a medium. The communication method includes that a server establishes a connection and feeds back a display control in response to requests of a first terminal and a second terminal; then, the server feeds back function feedback information in response to a function request of the first terminal, and feeds back function feedback information in response to a menu request of the second terminal; and the servers presents multiple interface components and maintains and updates each interface component in response to management operation of a third user.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSID).

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).

Abstract: Embodiment of present invention provide an optical subassembly that includes a first, a second, and a third band filter (BF) each having a common port (CP), a port-A (PA), and a port-B (PB). The PA of the second BF is connected to the PA of the third BF and the PB of the first BF is connected to the PB of the third BF. The optical subassembly is adapted to route a first optical signal of a blue band from the PA to the CP of the first BF; to route the first optical signal from the CP of the second BF to the CP of the third BF; to route a second optical signal of a red band from the CP of the third BF to the CP of the first BF; and to route the second optical signal from the CP to the PB of the second BF.

Abstract: A cell reselection method implemented by a terminal includes: camping on a first cell, where a first frequency of the first cell corresponds to a first PLMN; when the terminal device detects that a second cell satisfies a cell reselection condition and a second PLMN of the second cell and the first PLMN are not EPLMNs, skipping performing an action of reselection to the second cell, and adding the second cell to a barred list, where a second frequency of the second cell corresponds to a second PLMN; and when the terminal device detects that a third cell satisfies the cell reselection condition, and a third PLMN of the third cell and the first PLMN are EPLMNs, performing, an action of reselection to the third cell, where the third cell corresponds to the second frequency, and the third PLMN includes the first PLMN and the second PLMN.

Abstract: A pre-training service system is provided. The pre-training service system includes: a producer service module configured to provide a model producer with a model pre-training process for a pre-training dataset and generate a corresponding pre-training model; an optimizer service module configured to optimize the pre-training model according to a fine-tuning dataset provided by a model optimizer and obtain an optimized model; and a consumer service module configured to provide a model consumer with a service interface for the pre-training model or the optimized model, wherein the pre-training model or the optimized model is configured to perform inference on data provided by the model consumer and output a model prediction result.

Abstract: The method for optimizing a light source in integrated circuit manufacturing, includes following steps: S1, providing an initial light source; S2, performing region segmentation according to light intensity distribution of the initial light source to obtain a plurality of sub light source regions; S3, providing at least two matching patterns and matching them with each sub light source region to obtain at least two matching results corresponding to each sub light source region; S4, performing calculating based on the at least two matching results and each sub light source region to obtain a best matching pattern corresponding to each sub light source region; and S5, generating a light source to be optimized based on the best matching pattern corresponding to each sub light source region.

Abstract: Embodiment of present invention provide an optical subassembly that includes a first, a second, and a third band filter (BF) each having a common port (CP), a port-A (PA), and a port-B (PB). The PA of the second BF is connected to the PA of the third BF and the PB of the first BF is connected to the PB of the third BF. The optical subassembly is adapted to route a first optical signal of a blue band from the PA to the CP of the first BF; to route the first optical signal from the CP of the second BF to the CP of the third BF; to route a second optical signal of a red band from the CP of the third BF to the CP of the first BF; and to route the second optical signal from the CP to the PB of the second BF.

Abstract: Example embodiments relate to systems and methods for analog-to-digital signal conversion. One embodiment includes a system for analog-to-digital signal conversion. The system includes an analog input signal. The system also includes a digital-to-analog converter configured to generate a reference signal. Further, the system includes an amplifier configured to amplify an error signal that includes a difference between the analog input signal and the reference signal. Additionally, the system includes a level-crossing based sampling circuit that includes a first comparator configured to compare the error signal with respect to a first reference level, and a second comparator configured to compare the error signal with respect to a second reference level, thereby generating event-based reset signals corresponding to a plurality of sampling instances in order to reset the digital-to-analog converter.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.

Abstract: The present disclosure describes how a master beacon having a known UUID can be used to capture beacons within its range and superimpose a systematic address scheme on those beacons. The superimposed address scheme can then be used as a proxy for the individual beacons when developing applications that make use of the beacons. A master beacon automatically detects each beacon in a plurality of beacons and, for a set of beacons in the plurality of beacons, automatically changes either the first profile identifier or the second profile identifier for each beacon in the set of beacons. The change is such that the first profile identifier or the second profile identifier is identical for each beacon in the set of beacons and is also associated with the master beacon.